CoChat

Tumor fraction in cell-free DNA as a biomarker in prostate cancer

Open access
Choudhury, Atish D., Werner, Lillian, Francini, Edoardo, Wei, Xiao X., Ha, Gavin, Freeman, Samuel S., Rhoades, Justin, Reed, Sarah C., Gydush, Gregory, Rotem, Denisse, Lo, Christopher, Taplin, Mary-Ellen, Harshman, Lauren C., Zhang, Zhenwei, O’Connor, Edward P., Stover, Daniel G., Parsons, Heather A., Getz, Gad, Meyerson, Matthew, Love, J. Christopher, Hahn, William C., Adalsteinsson, Viktor A. · 2018 · JCI Insight
Cited by 139

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Tumor content in circulating cell-free DNA (cfDNA) is a promising biomarker, but longitudinal dynamics of tumor-derived and non-tumor-derived cfDNA through multiple courses of therapy have not been well described. METHODS: CfDNA from 663 plasma samples from 140 patients with castration-resistant prostate cancer (CRPC) was subject to sparse whole genome sequencing. Tumor fraction (TFx) estimated using the computational tool ichorCNA was correlated with clinical features and responses to therapy. RESULTS: TFx associated with the number of bone metastases (median TFx = 0.014 with no bone metastases, 0.047 with 1-3 bone metastases, 0.190 for 4+ bone metastases; P < 0.0001) and with visceral metastases (P < 0.0001). In multivariable analysis, TFx remained associated with metastasis location (P = 0.042); TFx was positively correlated with alkaline phosphatase (P = 0.0227) and negatively correlated with hemoglobin (Hgb) (P < 0.001), but it was not correlated with prostate specific antigen (PSA) (P = 0.75). Tumor-derived and non-tumor-derived cfDNA track together and do not increase with generalized tissue damage from chemotherapy or radiation at the time scales examined. All new treatments that led to ≥30% PSA decline at 6 weeks were associated with TFx decline when baseline TFx was >7%; however, TFx in patients being subsequently maintained on secondary hormonal therapy was quite dynamic. CONCLUSION: TFx correlates with clinical features associated with overall survival in CRPC, and TFx decline is a promising biomarker for initial therapeutic response. TRIAL REGISTRATION: Dana-Farber/Harvard Cancer Center (DF/HCC) protocol no. 18-135. FUNDING: Wong Family Award in Translational Oncology, Dana Farber Cancer Institute Medical Oncology grant, Gerstner Family Foundation, Janssen Pharmaceuticals Inc., and Koch Institute Support (core) grant P30-CA14051 from the National Cancer Institute (NCI).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci.insight.122109

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 139

Metadata

Authors
Choudhury, A. D., Werner, L., Francini, E., Wei, X. X., Ha, G., Freeman, S. S., Rhoades, J., Reed, S. C., Gydush, G., Rotem, D., Lo, C., Taplin, M.-E., Harshman, L. C., Zhang, Z., O’Connor, E. P., Stover, D. G., Parsons, H. A., Getz, G., Meyerson, M., Love, J. C., Hahn, W. C., & Adalsteinsson, V. A.
Venue
JCI Insight
Published
2018-11-02
Volume
3
Issue
21
ISSN
2379-3708 (ISSN-L)
OpenAlex
W2899109449
Cited by
139
References
3
FWCI
3.52
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tumor fraction in cell-free DNA as a biomarker in prostate cancer. https://app.cochat.ai/papers/10.1172/jci.insight.122109
The paper
Choudhury, A. D., Werner, L., Francini, E., Wei, X. X., Ha, G., Freeman, S. S., Rhoades, J., Reed, S. C., Gydush, G., Rotem, D., Lo, C., Taplin, M.-E., Harshman, L. C., Zhang, Z., O’Connor, E. P., Stover, D. G., Parsons, H. A., Getz, G., Meyerson, M., . . . Adalsteinsson, V. A. (2018). Tumor fraction in cell-free DNA as a biomarker in prostate cancer. JCI Insight. https://doi.org/10.1172/jci.insight.122109

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.